Call for Abstracts: Society for Immunotherapy of Cancer 27th Annual Meeting
October 26-28, 2012 North Bethesda, Maryland
The SITC 27th Annual Meeting allows for scientific exchange of the most cutting-edge preclinical and clinical data on immunotherapies and biological therapy of cancer. The program included dynamic presentations, interactive panel discussions and scientific posters on the most timely topics in cancer immunotherapy as well as vital information on clinical trial design and regulatory issues to advance collaboration and translation of cancer immunotherapies.
SITC is ideally positioned to meet the identified needs of our attendees. SITC’s strength lies in its history of organizing successful scientific conferences that gather clinicians and scientists from around the globe to interact and discuss the most important issues in cancer immunotherapy. By addressing these needs, SITC advances effective, efficient research and interaction on promising cancer therapies with biological and immunological agents. Through its integrated programs, SITC promotes productive collaboration among scientists and with other organizations in the field. Ultimately this scientific exchange and collaborative environment will lead to better cancer patient outcomes with novel cancer immunotherapies.
The SITC 27th Annual Meeting program format and content is designed to address identified needs/practice gaps and promotes:
Exchange between basic and clinical researchers, thus improving the caliber of the science and promoting translation
Discussion on potential hurdles in cancer immunotherapy from the trial design and regulatory perspective
Integrated understanding of the state of cancer immunotherapy research in today’s environment, identification of potential funding opportunities, and mentoring of junior investigators
Discussion of novel therapies and applications based on the research presented
Interactions with industry to promote access to novel agents for clinical development
Intended Audience
The audience for this program is basic and clinical investigators from academic institutions, industry and regulatory agencies, including clinicians, basic and translational researchers, graduate students, postdoctoral fellows, and allied health professionals involved in cancer research.
Program Goals
Exchange information on the most recent advances in tumor immunology and cancer immunotherapy
Convey recent advances in biology and immunotherapy as they relate to specific cancers and various immunotherapy modalities, cell subsets, animal models, and aspects of negative regulation in the tumor microenvironment
Identify promising research opportunities, new techniques and clinical applications incorporating these advances
Establish dialogue between academia, industry and government on these advances
Expected Learner Outcomes
Upon completion of this program, the participants will be able to:
Summarize the most recent advances in tumor immunology and cancer immunotherapy
Integrate recent advances in cancer immunology and immunotherapy into basic, clinical and translational research
Incorporate new research and techniques into clinical applications for cancer immunotherapy
Establish and solidify collaborations among the various members of academia, industry, government and clinical practices to promote clinical evaluation of these advances in more efficient trials
Abstracts
Each year, SITC has an open call for abstract submission for the SITC 27th Annual Meeting.
Submitting an abstract is free to members and non-members alike, so all are encouraged to submit. By submitting an abstract, you will be eligible to present a poster during the SITC 27th Annual Meeting and will be in consideration for one of the oral abstract presentation slots available in the plenary and concurrent sessions each day of the program. In addition, should you meet the criteria, you may be eligible for a Young Investigator Travel Award and possibly in contention for the SITC Presidential Award.
The deadline to submit an abstract is July 11, 2012.
Abstract Categories
Adoptive T Cell Transfer and Cell Therapy as Cancer Immunotherapy (CARS)
Combining Immunotherapy and Other Therapies
DC Subsets / Cancer Vaccines
Immunity of Oncolytic Viruses
Immunotherapy Combinations *
Innate Immunity in Cancer *
Single Cell High Throughput Technologies Immune Monitoring
T Cell Manufacture and Potency Testing
T Cell Modulating Strategies
Targeted Therapies and Anti-Tumor Immunity *
Targeting Immune Suppression
Therapeutic Monoclonal Antibodies in Cancer *
Tumor Microenvironment *
Tumor Vasculature, Chemokines and Lymphocyte Trafficking to the Tumor *
* Denotes poster only category. Abstracts submitted in these categories will be eligible for poster presentation only. However, abstracts submitted in these categories and noted eligible for Young Investigator Awards will be considered for both poster and oral presentations.
Abstracts submission for the SITC 27th Annual Meeting runs May 7 - July 11, 2012 through the SITC website.
